If you are a health care professional affiliated with an employer, institution or committee, or practicing in a state that restricts what items you may receive from manufacturers, we ask that you do not accept or download any restricted items from this site. If you are a health care provider practicing in Vermont, we are required by state law to deny you permission to download any items or review any journal articles made available on this site.
Evaluation of the Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to losartan: Two Multicenter, Double-blind, Randomized, Parallel-group, Forced-titration Studies.
CLAIM I and CLAIM II - The antihypertensive effects of candesartan cilexetil and losartan potassium at their highest recommended doses administered once daily were compared in two 8-week, randomized, double-blind trials. In a total of 1263 patients with mild to moderate hypertension, who were not receiving other antihypertensive therapy, candesartan cilexetil 32 mg lowered systolic and diastolic blood pressure by 2 to 3 mm Hg on average more than losartan potassium 100 mg, when measured at the time of either peak or trough effect. The primary end point for each study was mean change in trough SiDBP from baseline at Week 8. In both studies, systolic and diastolic blood pressure was reduced significantly vs losartan (P<.05). The least squares mean baseline trough sitting blood pressure for the overall treatment group was 152.3/100.0 mm Hg and 152.9/100.3 mm Hg in CLAIM I and CLAIM II, respectively.15,16
This product information is intended for US health care professionals only.
Atacand and Atacand HCT are registered trademarks of the AstraZeneca group of companies. ©2016 AstraZeneca. All rights reserved. 2005404-3250804 Last Updated 6/16
Manufactured under the license from Takeda Pharmaceutical Company, Ltd. by: AstraZeneca AB, S-151, 85 Södertälje, Sweden